79 related articles for article (PubMed ID: 2471542)
1. The proteinase inhibitor pepstatin A inhibits formation of reverse transcriptase in H9 cells infected with human immunodeficiency virus 1.
Grinde B; Hungnes O; Tjøtta E
AIDS Res Hum Retroviruses; 1989 Jun; 5(3):269-74. PubMed ID: 2471542
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of HIV replication in cell culture by the specific aspartic protease inhibitor pepstatin A.
von der Helm K; Gürtler L; Eberle J; Deinhardt F
FEBS Lett; 1989 Apr; 247(2):349-52. PubMed ID: 2469601
[TBL] [Abstract][Full Text] [Related]
3. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus.
Ichimura H; Levy JA
Virology; 1995 Aug; 211(2):554-60. PubMed ID: 7544050
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 proteinase is required for synthesis of pro-viral DNA.
Baboonian C; Dalgleish A; Bountiff L; Gross J; Oroszlan S; Rickett G; Smith-Burchnell C; Troke P; Merson J
Biochem Biophys Res Commun; 1991 Aug; 179(1):17-24. PubMed ID: 1652947
[TBL] [Abstract][Full Text] [Related]
5. Antiviral action of oligodeoxyguanylic acids against human immunodeficiency virus type 1.
Fujihashi T; Sakata T; Kaji A; Kaji H
AIDS Res Hum Retroviruses; 1995 Apr; 11(4):461-71. PubMed ID: 7543270
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human immunodeficiency virus (HIV-1) replication in vitro by noncytotoxic doses of camptothecin, a topoisomerase I inhibitor.
Priel E; Showalter SD; Blair DG
AIDS Res Hum Retroviruses; 1991 Jan; 7(1):65-72. PubMed ID: 1707642
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents.
Yamamoto N; Schols D; De Clercq E; Debyser Z; Pauwels R; Balzarini J; Nakashima H; Baba M; Hosoya M; Snoeck R
Mol Pharmacol; 1992 Dec; 42(6):1109-17. PubMed ID: 1282664
[TBL] [Abstract][Full Text] [Related]
8. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
Back NK; Nijhuis M; Keulen W; Boucher CA; Oude Essink BO; van Kuilenburg AB; van Gennip AH; Berkhout B
EMBO J; 1996 Aug; 15(15):4040-9. PubMed ID: 8670908
[TBL] [Abstract][Full Text] [Related]
9. Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection.
Lambert DM; Bartus H; Fernandez AV; Bratby-Anders C; Leary JJ; Dreyer GB; Metcalf BW; Petteway SR
Antiviral Res; 1993 Aug; 21(4):327-42. PubMed ID: 7692816
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human immunodeficiency virus type 1 replication by 7-methyl-6,8-bis(methylthio)pyrrolo[1,2-a]pyrazine, an in vivo metabolite of oltipraz.
Prochaska HJ; Bornmann WG; Baron P; Polsky B
Mol Pharmacol; 1995 Jul; 48(1):15-20. PubMed ID: 7542738
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A.
Seelmeier S; Schmidt H; Turk V; von der Helm K
Proc Natl Acad Sci U S A; 1988 Sep; 85(18):6612-6. PubMed ID: 3045820
[TBL] [Abstract][Full Text] [Related]
12. The effect of trimeric 2',5'-oligoadenylic acid and its epoxy-derivative on human immunodeficiency virus (HIV-1) reproduction and retroviruses reverse transcriptase activity.
Tkachuk ZYu ; Rybalko SL; Semernikova LI; Tkachuk VV; Zavelevich MP; Tkachuk LV; Eremenko T; Mikhailopulo IA; Matsuka GK
New Microbiol; 1998 Apr; 21(2):197-201. PubMed ID: 9579344
[TBL] [Abstract][Full Text] [Related]
13. In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha.
Pagano PJ; Chong KT
J Infect Dis; 1995 Jan; 171(1):61-7. PubMed ID: 7528253
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues.
Meek TD; Lambert DM; Dreyer GB; Carr TJ; Tomaszek TA; Moore ML; Strickler JE; Debouck C; Hyland LJ; Matthews TJ
Nature; 1990 Jan; 343(6253):90-2. PubMed ID: 1688646
[TBL] [Abstract][Full Text] [Related]
15. Modified oligopeptides designed to interact with the HIV-1 proteinase inhibit viral replication.
Grinde B; Hungnes O; Tjøtta E
Arch Virol; 1990; 114(3-4):167-73. PubMed ID: 2241573
[TBL] [Abstract][Full Text] [Related]
16. The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication.
Su J; Naghavi MH; Jejcic A; Horal P; Furuta Y; Wu YP; Li SL; Hall WW; Goobar-Larsson L; Svennerholm B; Vahlne A
J Hum Virol; 2001; 4(1):8-15. PubMed ID: 11213934
[TBL] [Abstract][Full Text] [Related]
17. All-trans retinoic acid attacks reverse transcriptase resulting in inhibition of HIV-1 replication.
Maeda Y; Yamaguchi T; Hijikata Y; Morita Y; Tanaka M; Hirase C; Takai S; Tatsumi Y; Kanamaru A
Hematology; 2007 Jun; 12(3):263-6. PubMed ID: 17558705
[TBL] [Abstract][Full Text] [Related]
18. Anti-AIDS agents, 2: Inhibitory effects of tannins on HIV reverse transcriptase and HIV replication in H9 lymphocyte cells.
Nonaka G; Nishioka I; Nishizawa M; Yamagishi T; Kashiwada Y; Dutschman GE; Bodner AJ; Kilkuskie RE; Cheng YC; Lee KH
J Nat Prod; 1990; 53(3):587-95. PubMed ID: 1698933
[TBL] [Abstract][Full Text] [Related]
19. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of HIV infection by baicalin--a flavonoid compound purified from Chinese herbal medicine.
Li BQ; Fu T; Yan YD; Baylor NW; Ruscetti FW; Kung HF
Cell Mol Biol Res; 1993; 39(2):119-24. PubMed ID: 7693133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
